STAAR Surgical Announces U.S. FDA Approval of EVO Visian® Implantable Collamer® Lenses

 STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today announced that the U.S. Food and Drug Administration (FDA) has granted approval of the EVO/EVO+ Visian® Implantable Collamer® Lens (“EVO”) for the correction of myopia and myopia with astigmatism. Myopia, which is also known as nearsightedness or the need for distance vision correction, is the most common vision disorder globally and its prevalence is rapidly growing.1 An estimated 100 million U.S. adults ages 21 to 45 who have myopia are potential candidates for EVO, a biocompatible implantable lens that corrects distance vision.2

https://www.businesswire.com/news/home/20220328005207/en/STAAR-Surgical-Announces-U.S.-FDA-Approval-of-EVO-Visian%C2%AE-Implantable-Collamer%C2%AE-Lenses